Skip to content

Research at St Andrews

Balance Right in Multiple Sclerosis (BRiMS): a guided self-management programme to reduce falls and improve quality of life, balance and mobility in people with secondary progressive multiple sclerosis: a protocol for a feasibility randomised controlled trial

Research output: Contribution to journalArticle

DOI

Open Access permissions

Open

Author(s)

H. Gunn, J. Andrade, L. Paul, L. Miller, S. Creanor, C. Green, J. Marsden, P. Ewings, M. Berrow, J. Vickery, A. Barton, B. Marshall, J. Zajicek, J. A. Freeman

School/Research organisations

Abstract

Background:  Impaired mobility is a cardinal feature of multiple sclerosis (MS) and is rated by people with MS as their highest priority. By the secondary progressive phase, balance, mobility and physical activity levels are significantly compromised; an estimated 70% of people with secondary progressive MS fall regularly. Our ongoing research has systematically developed ‘Balance Right in MS’ (BRiMS), an innovative, manualised 13-week guided self-management programme tailored to the needs of people with MS, designed to improve safe mobility and minimise falls. Our eventual aim is to assess the clinical and cost effectiveness of BRiMS in people with secondary progressive MS by undertaking an appropriately statistically powered, multi-centre, assessor-blinded definitive, randomised controlled trial. This feasibility study will assess the acceptability of the intervention and test the achievability of running such a definitive trial.
Methods/design:  This is a pragmatic multi-centre feasibility randomised controlled trial with blinded outcome assessment. Sixty ambulant people with secondary progressive MS who self-report two or more falls in the previous 6 months will be randomly allocated (1:1) to either the BRiMS programme plus usual care or to usual care alone. All participants will be assessed at baseline and followed up at 15 weeks and 27 weeks post-randomisation.

The outcomes of this feasibility trial include:

• Feasibility outcomes, including trial recruitment, retention and completion

• Assessment of the proposed outcome measures for the anticipated definitive trial (including measures of walking, quality of life, falls, balance and activity level)

• Measures of adherence to the BRiMS programme

• Data to inform the economic evaluation in a future trial

• Process evaluation (assessment of treatment fidelity and qualitative evaluation of participant and treating therapist experience)

Discussion:  The BRiMS intervention aims to address a key concern for MS service users and providers. However, there are several uncertainties which need to be addressed prior to progressing to a full-scale trial, including acceptability of the BRiMS intervention and practicality of the trial procedures. This feasibility trial will provide important insights to resolve these uncertainties and will enable a protocol to be finalised for use in the definitive trial.

Close

Details

Original languageEnglish
Article number26
Number of pages12
JournalPilot and Feasibility Studies
Volume4
DOIs
StatePublished - 27 Jul 2017

    Research areas

  • Secondary progressive multiple sclerosis, Exercise, Self-management, Mobility, Accidental falls, Balance, Quality of life, Feasibility randomised controlled trial

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Time-and region-specific season of birth effects in multiple sclerosis in the United Kingdom

    Cruz, P. M. R., Matthews, L., Boggild, M., Cavey, A., Constantinescu, C. S., Evangelou, N., Giovannoni, G., Gray, O., Hawkins, S., Nicholas, R., Oppenheimer, M., Robertson, N., Zajicek, J., Rothwell, P. M. & Palace, J. 1 Aug 2016 In : JAMA Neurology. 73, 8, p. 954-960 7 p.

    Research output: Contribution to journalArticle

  2. Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis

    Zeissler, M-L., Eastwood, J., McCorry, K., Hanemann, C. O., Zajicek, J. P. & Carroll, C. B. 27 Jun 2016 In : Oncotarget. 7, 29, p. 46603-46614 12 p.

    Research output: Contribution to journalArticle

  3. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease

    McGhee, D. J. M., Ritchie, C. W., Zajicek, J. P. & Counsell, C. E. 16 Jun 2016 In : BMC Neurology. 16, p. 1-13 13 p., 92

    Research output: Contribution to journalArticle

  4. Standing up in multiple sclerosis (SUMS): protocol for a multi-centre randomised controlled trial evaluating the clinical and cost effectiveness of a home-based self-management standing frame programme in people with progressive multiple sclerosis

    Freeman, J. A., Hendrie, W., Creanor, S., Jarrett, L., Barton, A., Green, C., Marsden, J., Rogers, E. & Zajicek, J. 5 May 2016 In : BMC Neurology. 16, p. 1-10 10 p., 62

    Research output: Contribution to journalArticle

  5. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study

    O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Kappos, L., Bouchard, J-P., Lebrun-Frenay, C., Mares, J., Benamor, M., Thangavelu, K., Liang, J., Truffinet, P., Lawson, V. J., Wolinsky, J. S., Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas & Zajicek, J. P. 8 Mar 2016 In : Neurology. 86, 10, p. 920-930 11 p.

    Research output: Contribution to journalArticle

Related by journal

ID: 250573102